+0.15 (+0.8%)
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Dated clinical, regulatory & corporate events for Apollomics Inc.
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APL-101 Small molecule | Solid Tumors | Phase 2 | NCT03175224 | 10% | $134M | RECRUITING | 497 | STALLED | D (39) | Nov 30, 2026 | MODERATE_RISK | LOW May 26, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vebreltinib | non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-27 | over 282 subjects have enrolled in the SPARTA study; over 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials Read More | Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress Read More | |
vebreltinib | non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-27 | over 282 subjects have enrolled in the SPARTA study; over 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials Read More | Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress Read More | |
vebreltinib | non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-27 | over 282 subjects have enrolled in the SPARTA study; over 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials Read More | Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Apollomics Inc. has received a notice from Nasdaq indicating non-compliance with the minimum market value requirement. The company has a 180-day period to regain compliance or face delisting. Separately, Apollomics terminated its collaboration with Launxp International due to a breach, regaining rights to its lead asset, vebreltinib, in Asia.
Read more →Apollomics reported its financial results for 2025, highlighting the ongoing Phase 2 studies of vebreltinib, a promising c-MET inhibitor. The company plans to submit an IND application for accelerated approval in 2027. Despite a significant net loss, Apollomics has made strides in cost reduction and management restructuring, aiming to enhance its clinical pipeline.
Read more →Apollomics Inc. has announced a $2.0 million unsecured Convertible Promissory Note with its CEO, Mr. Hung-Wen Chen. The funds will be used to support its clinical development programs and corporate operations. The arrangement includes a conversion provision that allows the note to convert into equity upon the closing of subsequent financing. Independent review by the Audit Committee and Board suggests a strategic move for future growth.
Read more →Apollomics Inc. reported its financial results for the first half of 2025, revealing a net loss of $12.5 million, a substantial decrease from $35.2 million in the same period last year. The company noted that its cash reserves are adequate to sustain operations through the third quarter of 2026, despite a significant drop in cash and equivalents from the previous year. R&D expenses saw a dramatic decline, while G&A expenses did increase compared to 2024.
Read more →Apollomics Inc. released its unaudited condensed consolidated interim financial statements for the first half of 2025, revealing a continued net loss of $12,536. Despite generating revenue of $8,500, the company's total assets have decreased to $11,119, leading to negative equity of $(4,398). High research and development expenses, alongside other liabilities, signal ongoing financial challenges for the clinical-stage biotechnology company focused on oncology therapies.
Read more →Apollomics Inc. has announced a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited regarding a litigation case that arose from a request for redemption of preferred shares prior to the company's merger with Maxpro Capital Acquisition Corporation. The settlement, which resolves all claims, involves Apollomics agreeing to pay a total of $5 million plus legal expenses over two years. This is a significant reduction from the original $40 million claim filed in the Grand Court of the Cayman Islands.
Read more →Apollomics Inc. (APLM) has entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited, fully resolving previous litigation in the Cayman Islands concerning the redemption of preferred shares prior to a merger. The company will pay TWVC $5 million in installments over two years, along with approximately $879,757.78 for legal expenses, significantly lowering potential damages from an initial claim of $40 million. TWVC will withdraw all claims against Apollomics, and the agreement is pending court approval.
Read more →Apollomics Inc. has announced changes to its Board of Directors, following the resignation of Mr. Po-Jen Hsueh, which was not due to any disagreement. Dr. Ya-Chi (Claudia) Huang has been appointed as his replacement and will serve on the Audit Committee and Nominating and Corporate Governance Committee. Dr. Huang brings significant experience in biotechnology investment and corporate governance, having previously served in key roles at Maxpro Ventures and Diamond Biofund.
Read more →Apollomics Inc. announced changes to its Board of Directors, including the resignation of Mr. Po-Jen Hsueh and the appointment of Dr. Ya-Chi (Claudia) Huang to fill the vacancy. Dr. Huang will also serve on the Audit Committee and Nominating and Corporate Governance Committee. Her background in biotechnology investment and corporate governance is expected to provide valuable insights to the board. The company's board now consists of seven members, with several being independent directors.
Read more →Apollomics Inc. has announced its continued listing on the Nasdaq stock market after successfully meeting the requirements set by the exchange. The company, based in California, specializes in developing targeted therapies for various cancers. Their lead candidate, Vebreltinib, is currently undergoing Phase II trials in the U.S. and other countries.
Read more →Apollomics Inc. (Nasdaq: APLM) has announced its application to list on The Nasdaq Stock Market. The company specializes in developing innovative therapies for cancer, particularly focusing on vebreltinib, a c-Met inhibitor. This submission follows the company's recent progress in clinical trials, aiming to enhance treatment options for patients with various cancers.
Read more →Apollomics Inc. announced that it has received confirmation from Nasdaq that it complies with continued listing requirements, leading to the cancellation of a scheduled appeal hearing regarding a prior delisting notification. This decision allows Apollomics' securities to remain listed and continue trading on the Nasdaq Stock Market. The company is focused on developing oncology therapies, including its lead program vebreltinib.
Read more →Apollomics Inc. has announced significant progress in its clinical development, particularly with APL-101 (vebreltinib), which is currently undergoing a Phase 2 trial. The company aims to enhance its pipeline of therapies targeting various cancers, including non-small cell lung cancer. Recent results indicate positive outcomes in patient responses, prompting further investment and strategic planning.
Read more →Apollomics Inc. has announced an operational update, reversing its previous decision to wind up operations after securing $4.1 million in funding. The company is committed to continuing its global Phase 2 trial of APL-101 (vebreltinib) and has appointed a new management team. Apollomics aims to leverage its clinical developments and pursue regulatory submissions in various markets.
Read more →Apollomics Inc. received a delisting notification from Nasdaq, which deemed the company a 'public shell' due to perceived operational deficiencies. The company plans to appeal this decision while asserting its activity in developing oncology therapies, specifically vebreltinib. Despite recent challenges, including a past intention to wind up business, Apollomics has restructured operations following a recent investment. A formal appeal will be filed by September 25, 2025, as the company seeks to maintain its Nasdaq listing.
Read more →Apollomics Inc. has called for an extraordinary general meeting of shareholders to take place on September 4, 2025. The primary agenda item is the Winding Up Proposal, which aims to dissolve the company due to its inability to sustain operations or meet financial obligations. Shareholders are being urged to vote on the proposal, as well as an Adjournment Proposal, which would provide time to gather sufficient votes for the Winding Up. The Board believes this is necessary for the best recovery for the company's creditors.
Read more →Apollomics Inc. reported its financial results for the fiscal year 2024, highlighting significant clinical updates and business progress. The company announced a partnership with LaunXP to enhance the clinical dataset for its drug vebreltinib, which shows promise in treating non-small cell lung cancer. Additionally, preliminary results for various tumor types indicate potential efficacy, although there are inherent risks and uncertainties in clinical development and commercialization.
Read more →Apollomics has entered a development and commercialization agreement with LaunXP for vebreltinib, a c-Met inhibitor, in combination with an EGFR inhibitor for NSCLC treatment in Asia. The agreement includes an upfront payment of $10 million, with additional milestone payments possible. Both companies aim to improve patient outcomes by delaying EGFRi resistance.
Read more →Apollomics Inc. has announced the results from its Phase 3 bridging trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia conducted in China. Unfortunately, the trial failed to demonstrate any clinical benefit, with a median overall survival of 9.3 months in the treatment arm versus 14.3 months in the control arm. Consequently, Apollomics is concluding the uproleselan program and anticipates future expenses to be below $500,000. The company plans to present the full trial results at a future medical conference.
Read more →Apollomics Inc. announced on December 10, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. This status was confirmed after the company's Class A ordinary shares maintained a closing bid price of $1.00 or greater for ten consecutive business days. As a result, Nasdaq will continue to list Apollomics shares, providing a positive outlook for the company moving forward.
Read more →Apollomics Inc. has announced that its shareholders approved a 1-for-100 reverse share split, which will take effect on November 25, 2024. The company's Board of Directors is implementing this split as part of a strategy to improve share value perception, while also increasing its authorized share capital significantly. This move allows shareholders to consolidate their holdings, with shares trading on a split-adjusted basis thereafter. Nonetheless, the potential effectiveness of this change in enhancing stock performance remains uncertain.
Read more →Apollomics Inc. has called for an extraordinary general meeting on November 14, 2024, to discuss a proposed reverse share split aimed at increasing the per-share trading price. This action is intended to help the company meet the NASDAQ minimum bid price requirement of $1.00, as it currently trades below this threshold. If compliance is not achieved by the deadline of January 13, 2025, the company faces delisting. Shareholders will vote on the proposal, which also aims to enhance the company's attractiveness to institutional investors.
Read more →Apollomics Inc. presented promising data on vebreltinib at the 2024 ESMO Congress, showcasing its efficacy in non-small cell lung cancer (NSCLC) patients with METex14 skipping mutations. The global Phase 2 SPARTA-II trial revealed an overall response rate of 66.7% in treatment-naive patients, alongside favorable duration of response and progression-free survival rates. Vebreltinib demonstrated robust performance even in subgroups previously identified as less responsive to MET inhibitors. However, treatment-related adverse events were observed in a notable portion of patients.
Read more →Apollomics Inc. will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The CEO and CFO will lead the presentation, and it will also be available on demand starting September 9. The company is focused on innovative oncology therapies, including vebreltinib for non-small cell lung cancer and uproleselan for acute myeloid leukemia, which are currently in advanced clinical trials.
Read more →Apollomics Inc. reported its condensed consolidated interim financial statements for the six months ending June 30, 2024. The company saw a substantial decrease in total assets from $55.4 million at the end of December 2023 to $34.6 million as of June 30, 2024. Loss before taxation improved to $35.2 million from $150.7 million in the prior year, indicating some operational adjustments. However, the overall financial health appears to be concerning with significant accumulated losses and declining non-current assets.
Read more →Apollomics Inc. reported its financial results for the first half of 2024, highlighting continued clinical progress in its vebreltinib program. The company achieved a 43% objective response rate in a Phase 2 trial for non-CNS MET fusion tumors. However, it also faced challenges, as negative results from a pivotal Phase 3 study of uproleselan led to an impairment loss of $10.0 million. Despite the hurdles, Apollomics has sufficient cash to support operations until the third quarter of 2025.
Read more →Apollomics Inc. has announced positive preliminary data from its Phase 2 SPARTA trial of vebreltinib, showing a 43% objective response rate in patients with non-CNS MET fusion solid tumors. The trial included 14 patients, highlighting significant clinical results across various cancer types, particularly in non-small cell lung cancer. The company is optimistic about the drug's efficacy and is assessing further development opportunities as it continues to monitor trial participants.
Read more →Apollomics Inc. announced its participation in the Canaccord Genuity 44th Annual Growth Conference scheduled for August 13-15, 2024, in Boston, MA. CFO Matthew Plunkett will present the company’s progress and future plans on August 14, 2024. The presentation will provide insights into Apollomics' clinical-stage oncology therapies, including vebreltinib and uproleselan, both targeting difficult cancers. Investors interested in one-on-one meetings can contact their Canaccord Genuity representatives.
Read more →Apollomics Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement after its shares fell below $1.00. This extension lasts until January 13, 2025, and allows the company to fulfill certain financial and share price criteria. Apollomics will monitor its ordinary shares closely and assess options to meet the compliance standards, although there is no guarantee of success. The company is focused on developing oncology therapies aimed at addressing challenging cancer treatments.
Read more →Apollomics has announced a strategic shift in its focus to concentrate on the clinical development of vebreltinib for non-small cell lung cancer (NSCLC) patients with Met amplification mutations. This change involves leadership transitions, including the upcoming consulting roles for two key executives. The company anticipates significant reductions in ongoing expenses, enabling operations to be funded through the third quarter of 2025, while continuing to enroll patients in the SPARTA Phase 2 clinical trial. Vebreltinib is positioned as a promising treatment option for a variety of MET-altered tumors, reflecting the company's commitment to addressing unmet medical needs.
Read more →Apollomics Inc. presented positive data for vebreltinib at the 2024 ASCO Annual Meeting. The drug exhibited promising efficacy with a 75% overall response rate in NSCLC patients. In a separate trial for glioblastoma patients, vebreltinib showed a median overall survival of 6.31 months compared to 3.38 months in the chemotherapy group. The company remains optimistic about vebreltinib's clinical development, indicating potential as an effective treatment for various cancer types driven by c-MET alterations.
Read more →Apollomics Inc. has announced its participation in the 2024 BIO International Convention, set to take place from June 3-6 in San Diego, California. The company's presentation is scheduled for June 4 at 3:15 p.m., led by President and Executive Director, Sanjeev Redkar. This event provides a platform for Apollomics to showcase its ongoing development of oncology therapies, including promising drug candidates in the clinical stage. Attendees will also have the opportunity to meet with the company's management for more in-depth discussions.
Read more →Apollomics Inc. has announced a private placement financing expected to generate approximately $6 million in gross proceeds. This financing involves the issuance of 19,166,666 Class A ordinary shares. Additionally, Dr. Robert Lin has been appointed to the Board of Directors, bringing substantial experience in clinical trials and biotechnology. The company intends to use the proceeds to fund its pipeline programs and for general corporate purposes, while also noting the resignation of Jonathan Wang from the Board for personal reasons.
Read more →Apollomics, in partnership with Avistone, has gained approval from China’s National Medical Products Administration for vebreltinib, a first-in-class treatment for gliomas with the PTPRZ1-MET fusion gene. The approval follows positive results from the FUGEN trial, where vebreltinib demonstrated a median overall survival of 6.31 months, significantly outperforming standard treatments. This marks a significant milestone for the company as the drug is also being explored in the ongoing SPARTA trial with similar positive preliminary data for patients globally.
Read more →Apollomics Inc. presented promising data on vebreltinib, a selective MET kinase inhibitor, at the 2024 AACR Annual Meeting. The data revealed its effectiveness against various MET-altered tumors, showing potential to overcome treatment resistance in non-small cell lung cancer. Preclinical models demonstrated vebreltinib's significant anti-tumor activity, supporting its continued clinical development. Conditional approval from China's NMPA further highlights its potential as a novel cancer therapy.
Read more →Apollomics has announced poster presentations for its drug vebreltinib at the upcoming 2024 AACR Annual Meeting, scheduled for April 5-10 in San Diego. Vebreltinib, a brain-penetrating MET kinase inhibitor, has shown strong anti-tumor activity across various cancers and demonstrates a favorable safety profile in early clinical trials. The company aims to explore vebreltinib's potential in combination therapies, furthering its development in addressing c-MET dysregulated tumors.
Read more →Apollomics showcased its clinical advancements and financial results for the year ending December 31, 2023. Key highlights include the continued progress of the vebreltinib program for NSCLC and the completed patient enrollment for the uproleselan Phase 3 bridging study. Despite a net loss of $172.6 million in 2023, the company maintains that its cash reserves are adequate to fund operations through early 2025. Upcoming clinical data from its pipeline is eagerly anticipated.
Read more →Apollomics Inc. has announced that it will report its full year 2023 financial results on March 28, 2024, ahead of the market opening. The company's management will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. Apollomics is a clinical-stage biopharmaceutical firm focused on developing oncology therapies that target specific cancer pathways.
Read more →Apollomics Inc. announced the appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer, effective immediately. Plunkett, who has over 25 years of experience in the biopharmaceutical sector, is expected to significantly contribute to Apollomics' financial strategy and business development as the company pursues clinical and regulatory milestones for its drug candidates. Vebreltinib, aimed at treating advanced tumors, is positioned at the forefront of Apollomics' pipeline, addressing a critical area in oncology.
Read more →Apollomics Inc. has announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, where CEO Guo-Liang Yu and President Sanjeev Redkar will present virtually on February 14, 2024. The company is focused on developing drugs for difficult-to-treat cancers and currently has nine drug candidates in its pipeline, with six in clinical development. Investors can access the live webcast and arrange meetings with the management during the conference.
Read more →Apollomics Inc. received a notification from Nasdaq regarding a deficiency in meeting the minimum bid price requirement. The company has 180 days, until July 15, 2024, to remedy this situation and regain compliance. While the ordinary shares will continue to be traded, failing to meet the requirements could lead to delisting. Apollomics is actively monitoring its bid price and evaluating options to restore compliance.
Read more →Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, along with President Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference on January 18, 2024. The event will focus on the company's efforts in developing targeted therapies for challenging cancers. Investors will have access to a live webcast, and an archived replay will be available post-event.
Read more →Apollomics Inc. has completed enrollment for its Phase 3 bridging study of uproleselan, an E-selectin antagonist, aimed at treating relapsed/refractory acute myeloid leukemia in Chinese patients. The study involves 140 participants randomized between uproleselan combined with standard chemotherapy or placebo. Uproleselan is noted for its novel mechanism, potentially improving patient outcomes in a context where traditional therapies may lack effectiveness. The primary endpoint is overall survival, with additional measures assessing remission rates and treatment side effects.
Read more →Apollomics Inc. is set to present at the 2024 Biotech Showcase on January 8, 2024, led by Co-Founder and President Sanjeev Redkar, Ph.D. The company focuses on developing innovative therapies for tough-to-treat cancers, with six of its nine drug candidates currently in clinical development. Apollomics emphasizes targeting specific molecular pathways that may inhibit cancer growth, including lead candidates like vebreltinib and uproleselan. However, the company acknowledges risks related to regulatory changes and clinical results in their forward-looking statements.
Read more →Apollomics Inc. has presented interim data from two ongoing Phase 2 clinical trials of vebreltinib, an investigational drug for non-small cell lung cancer (NSCLC) patients with MetExon14 skipping mutation. The trials show promising overall response rates (ORR) of 64.5% in patients without co-occurring MET amplification and a notably higher rate of 85.7% in those with MET amplification. The data also highlight the generally acceptable safety profile of vebreltinib, although there has been a significant incidence of grade 3 or higher treatment-related adverse events. These findings suggest vebreltinib may address unmet medical needs in challenging-to-treat patient populations.
Read more →Apollomics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference scheduled for December 6, 2023. Company executives Guo-Liang Yu and Sanjeev Redkar are set to discuss their oncology drug candidates and future directions. Investors are invited to arrange meetings with management during the event, which will also be available for streaming and later replays. Apollomics is developing therapies aimed at challenging oncology cases, with several candidates in clinical stages.
Read more →Apollomics Inc. has announced a poster presentation at the 2023 IASLC North America Conference on Lung Cancer (NACLC) focusing on vebreltinib, a treatment for NSCLC with MET exon 14 skipping mutations. The data highlights vebreltinib's strong efficacy and safety profile, with successful outcomes reported in clinical trials. The company is exploring its use in combination with other therapies and across various tumor types, while monitoring its ongoing global clinical trial efforts.
Read more →Apollomics, through its partner Avistone Biotechnology, has received conditional approval from the National Medical Products Administration (NMPA) in China for vebreltinib to treat MET exon 14 skipping non-small cell lung cancer (NSCLC). This development is significant as it offers a new treatment option for patients facing limited choices. The company is also in discussions with the FDA for a New Drug Application based on clinical data from ongoing trials. However, commercialization outcomes remain uncertain due to the conditional nature of the approval and potential regulatory challenges in the US.
Read more →Apollomics Inc. has announced the expansion of its Phase 2 SPARTA study to include two new cohorts assessing vebreltinib's effectiveness in patients with non-small cell lung cancer and other solid tumors characterized by MET dysregulation. The new cohorts, C-2 and F, will investigate the combination of vebreltinib with EGFR inhibitors and the drug's monotherapy potential, respectively. With over 240 subjects already enrolled, this study aims to provide new treatment options for patients facing resistance to existing therapies. The company highlights the strategic importance of addressing significant gaps in treatment for these cancer types.
Read more →Apollomics Inc. announced positive efficacy results for vebreltinib in a glioblastoma multiforme patient with a PTPRZ-MET fusion, as reported at ESMO 2023. The patient demonstrated a Partial Response after 8 weeks of treatment with vebreltinib, raising hope for its potential as a new treatment for aggressive GBM variants. While these results are encouraging, the company cautions that they may not represent broader patient outcomes. They are currently working on a phase 2/3 study for further evaluation and have received a priority review for a New Drug Application from the NMPA.
Read more →Apollomics Inc. announced positive efficacy data for vebreltinib at the ESMO 2023 conference, showing a 75% overall response rate in NSCLC patients with MetEx14 skipping mutations. The Phase 2 KUNPENG clinical trial, conducted in collaboration with Avistone Biotechnology Ltd., revealed an impressive median duration of response of 15.9 months. Additionally, vebreltinib exhibited a rapid onset of therapeutic effect, with a median time to response of just one month. The drug is currently under review for NDA by NMPA in China.
Read more →Apollomics Inc. has announced the presentation of vebreltinib data at the upcoming ESMO 2023 Congress in Madrid. Two abstracts detailing preliminary safety and efficacy data from the Phase 2 KUNPENG trial for non-small cell lung cancer will be presented. Additionally, data from the APL-101-01 SPARTA study will also be included in a mini-oral presentation. This highlights the company's ongoing commitment to developing innovative oncology therapies.
Read more →Apollomics Inc. has reported its financial results for the first half of 2023, revealing a significant cash position but also a concerning increase in net losses. The company is working on pivotal clinical trials for its lead candidates, vebreltinib and uproleselan, with results expected later in the year. Despite rising operational costs following its public listing, the company is optimistic about generating key clinical data across its pipeline in 2023 and 2024.
Read more →Apollomics Inc. announced that its Co-Founder and President, Sanjeev Redkar, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. This presentation will highlight the company's progress in developing various oncology therapies. Apollomics has several products in clinical trials, including vebreltinib and uproleselan, targeting difficult cancers. Investors are encouraged to arrange meetings with the management during the event to discuss the company’s developments further.
Read more →Apollomics Inc. announced that its Co-Founder and President, Dr. Sanjeev Redkar, will speak at the 23rd Annual R. Bryan Miller Symposium on April 14, 2023. His presentation will focus on the HGF/c-Met pathway in cancer, underscoring its importance in overcoming treatment resistance in certain cancers. Apollomics is actively developing therapies, including APL-101, a c-Met inhibitor targeted at non-small cell lung cancer. The symposium will feature other notable speakers from prominent institutions, reflecting the event's significance in the field of chemical biology and organic chemistry.
Read more →Apollomics has successfully completed its business combination with Maxpro Capital Acquisition Corp., allowing its Class A ordinary shares and public warrants to begin trading on the Nasdaq under the symbols APLM and APLMW. This business combination was supported by a $21.65 million private investment in public equity, which enables Apollomics to advance its oncology drug pipeline. The company is focused on treatments for difficult-to-treat cancers, including lung cancer and acute myeloid leukemia, and is advancing multiple drug candidates through clinical trials.
Read more →FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA)
Read more →– Transaction values Apollomics at pre-money equity value of $899 million – Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple oncology programs
Read more →FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief S
Read more →FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host
Read more →FOSTER CITY, Calif. and HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairma
Read more →FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has bee
Read more →FOSTER CITY, Calif. and HANGZHOU, China and SHANGHAI, China, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of
Read more →FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, May 20, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch
Read more →- Fibrogen veteran brings global R&D expertise to Management Team - - Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy and commercialization expertise - FOSTER CITY, Calif. and HANGZHOU, China, March 09
Read more →FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been
Read more →FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement f
Read more →FOSTER CITY, Calif., HANGZHOU, China and HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion Therapeutics, Inc., a venture-backed,
Read more →- Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 - - EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) - FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, Calif., Feb. 09
Read more →FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting agents and immuno-oncology agents and their combination therapies, today announce
Read more →- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 (Uproleselan) - FOSTER CITY, Calif. and HANGZHOU, China, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmace
Read more →FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced APL-106 (uproleselan) has received Invest
Read more →- Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme - FOSTER CITY, Calif. and HANG
Read more →FOSTER CITY, Calif. and HANGZHOU, China, May 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced that Fabio M. Benedetti, M.D. has join
Read more →FOSTER CITY, Calif. and HANGZHOU, China, April 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced positive data for the Company’s mult
Read more →Wilson W. Cheung, CPA appointed Chief Financial Officer Debra L. Thoma Vallner, PhD, MBA named Senior Vice President, Development Operations FOSTER CITY, Calif. and HANGZHOU, China, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company comm
Read more →Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs New brand reinforces Apollomics’ mission to discover and develop novel medicines and effective combination therapies to improve the lives of cancer patients FOSTER CITY, Ca
Read more →